ReviewFrontiers in cellular and infection microbiology2021
Towards a Sustainable Vector-Control Strategy in the Post Kala-Azar Elimination Era.
Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Can floral nectars reduce transmission of Leishmania?PLoS neglected tropical diseases · 2022Pooled it
- Effectiveness of Long-lasting Insecticide-Impregnated Bed Nets in Controlling Phlebotomus argentipes in Sri Lanka: A Cluster Randomized Controlled Trial.The Journal of infectious diseases · 2025Trial
- Decision-making for indoor residual spraying in the post-elimination phase of visceral leishmaniasis in Nepal.PLoS neglected tropical diseases · 2026Article
- High Seropositivity to rK39 and Capture of Leishmania-Infected Sand Flies in Bihar and Jharkhand Emphasize the Need for Post-Elimination Surveillance of Visceral Leishmaniasis in India.The Journal of infectious diseases · 2026Article
- Biological Activity of Stilbenoids Against Fungal, Parasitic, and Viral Pathogens.Molecules (Basel, Switzerland) · 2026Review
- Adapting lessons from the Indian subcontinent to accelerate elimination of visceral leishmaniasis as a public health problem in East Africa.PLoS neglected tropical diseases · 2026Article
- Elimination of visceral leishmaniasis as a public health problem in Bangladesh: Lessons learned and questions remaining.PLoS neglected tropical diseases · 2026Review
- Targeting environmental determinants and settlements in public health planning for the containment of visceral leishmaniasis: a One Health perspective.Frontiers in public health · 2026Article
- Leishmaniasis.Nature reviews. Disease primers · 2025Review
- Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Understanding experiences of neglected tropical diseases of the skin: a mixed-methods study to inform intervention development in Ethiopia.BMJ global health · 2025Article
- Unravelling drug resistance in leishmaniasis: genomic adaptations and emerging therapies.Frontiers in molecular biosciences · 2025Review
- Knockdown resistance mutations in Phlebotomus argentipes sand flies in Bihar, India.Parasites & vectors · 2024Article
- Immunisation with TransgenicMicroorganisms · 2023Article
- Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.Frontiers in immunology · 2023Review
- A Composite Recombinant Salivary Proteins Biomarker for Phlebotomus argentipes Provides a Surveillance Tool Postelimination of Visceral Leishmaniasis in India.The Journal of infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Visceral leishmaniasis (VL) is a potentially deadly parasitic disease. In the Indian sub-continent, VL is caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.